Drug Database
Back to search

Netherlands· NL-ce31801b24d0

Dipentum 500 mg, tabletten

A olsalazine product containing olsalazine dinatrium, registered in Netherlands by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC A07EC03

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedDipentum 500 mg, tablettenATCA07EC03REGISTER NO.NL-ce31801b24d0PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about olsalazine dinatriumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Olsalazine is registered in 11 of 19 countries.

Countries holding a registration under ATC A07EC03 (olsalazine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search olsalazine products by name

Olsalazine · ATC A07EC03

11 / 19 countries

  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of olsalazine costs, country by country.

Normalised to the WHO defined daily dose (1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Olsalazine · price per daily dose (1 g)

USD · FX 28 Sept 2026

  • FR France$1.44
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
OLSALAZINE DINATRIUM
Manufacturer
Atnahs Pharma Netherlands B.V.
Country
Netherlands (NL)
ATC code
A07EC03
ATC class
Olsalazine
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    14363

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

110 interactions on record for olsalazine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check olsalazine against other medicinesHow interaction checks work

Olsalazine · interactions on record

110 records

  • 15 severe
  • 93 moderate
  • 2 minor

Most severe, free to view

  • CidofovirJ05AB12severe
  • Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
  • Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
  • SirolimusL01EG04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Olsalazine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All olsalazine products

Authorised across Europe · EMA

The same active substance is authorised in 9 EEA countries. Names it is sold under:

  • Germany · Dipentum
  • Denmark · Dipentum
  • Finland · Dipentum
  • France · Dipentum
  • United Kingdom (Northern Ireland) · Olsalazine Sodium Atnahs Pharma Uk
  • Ireland · Dipentum
  • Iceland · Dipentum
  • Norway · Dipentum
  • Sweden · Dipentum

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/baa16170-202b-4a8f-9aaa-60f6361cd777
GET /v1/drugs/baa16170-202b-4a8f-9aaa-60f6361cd777?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h14363_smpc.pdf",
  "strength": null,
  "atc_label": "Olsalazine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg14363",
  "excipients": [
    "CROSPOVIDON (E 1202)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON K 30 (E 1201)",
    "SILICIUMDIOXIDE (E 551)"
  ],
  "substances": [
    "OLSALAZINE DINATRIUM"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h14363.pdf",
  "authorised_at": "1991/05/01",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "14363",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about olsalazine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console